Center for Molecular Delivery, University of South Florida; Tampa, FL, USA.
Hum Vaccin Immunother. 2012 Nov 1;8(11):1729-33. doi: 10.4161/hv.21624. Epub 2012 Aug 16.
Non-viral in vivo administration of plasmid DNA for vaccines and immunotherapeutics has been hampered by inefficient delivery. Methods to enhance delivery such as in vivo electroporation (EP) have demonstrated effectiveness in circumventing this difficulty. However, the contact-dependent nature of EP has resulting side effects in animals and humans. Noncontact delivery methods should, in principle, overcome some of these obstacles. This report describes a helium plasma-based delivery system that enhanced humoral and cellular antigen-specific immune responses in mice against an intradermally administered HIV gp120-expressing plasmid vaccine (pJRFLgp120). The most efficient plasma delivery parameters investigated resulted in the generation of geometric mean antibody-binding titers that were 19-fold higher than plasmid delivery alone. Plasma mediated delivery of pJRFLgp120 also resulted in a 17-fold increase in the number of interferon-gamma spot-forming cells, a measure of CD8+ cytotoxic T cells, compared with non-facilitated plasmid delivery. This is the first report demonstrating the ability of this contact-independent delivery method to enhance antigen-specific immune responses against a protein generated by a DNA vaccine.
非病毒体内给药质粒 DNA 用于疫苗和免疫疗法一直受到低效传递的阻碍。增强传递的方法,如体内电穿孔 (EP),已经证明在规避这一困难方面是有效的。然而,EP 的接触依赖性在动物和人类中产生了副作用。非接触式传递方法原则上应该克服其中的一些障碍。本报告描述了一种基于氦等离子体的传递系统,该系统增强了小鼠对皮内给予的 HIV gp120 表达质粒疫苗 (pJRFLgp120) 的体液和细胞抗原特异性免疫反应。研究中最有效的等离子体传递参数导致抗体结合滴度的几何平均比单独给予质粒高出 19 倍。与非促进质粒传递相比,pJRFLgp120 的等离子体介导传递还导致干扰素-γ斑点形成细胞的数量增加了 17 倍,这是 CD8+细胞毒性 T 细胞的一个衡量标准。这是第一个证明这种非接触式传递方法能够增强针对 DNA 疫苗产生的蛋白质的抗原特异性免疫反应的报告。
Hum Vaccin Immunother. 2012-8-16
Immunol Cell Biol. 2010-9-14
Int J Mol Sci. 2023-12-30
Plasma Process Polym. 2020-10
ACS Chem Biol. 2017-5-19
Exp Ther Med. 2016-5
Bioelectrochemistry. 2015-6
Hum Vaccin Immunother. 2012-11-1
Annu Int Conf IEEE Eng Med Biol Soc. 2011
PLoS One. 2011-4-29
Curr Opin Immunol. 2011-4-27
Immunol Rev. 2011-1